Abstract | BACKGROUND: The nuclear factor-κB pathway is an important signaling pathway activated in multiple myeloma cells. Bortezomib inhibits nuclear factor-κB activation and is an important antimyeloma agent. Nevertheless, patients treated with this drug eventually relapse. We hypothesized that the nuclear factor-κB pathway may be associated with multiple myeloma and patients' responses to bortezomib. DESIGN AND METHODS: In this study we analyzed 26 polymorphism sites of nuclear factor-κB family member genes, IKBα, NFKB2, and TRAF3, in 527 unrelated Chinese Han subjects (252 with multiple myeloma and 275 controls) using a Sequenom MassARRAY genotyping assay, and examined the outcome of 83 patients treated with a bortezomib-based regimen. RESULTS: Single nucleotide polymorphisms in the TRAF3 rs12147254 A allele and a specific haplotype 1 of TRAF3 [GAACAG] are associated with a decreased risk of multiple myeloma (odds ratio 0.709, P<0.001, and odds ratio 0.543, P<0.0001), while TRAF3 haplotype 4 [GGACAG] was associated with an increased risk of development of multiple myeloma (odds ratio 2.099, P=0.001). Moreover, the TRAF3 rs11160707 GA+AA genotype was significantly associated with a better progression-free survival (P=0.018). Patients with the NFKB2 rs12769316 GA+AA genotype had a superior overall survival (P=0.020), while those with the rs1056890 CT+TT genotype had an inferior overall survival (P=0.037). In an exploratory analysis, patients with the GA+AA/CC/GG genotype at the rs12769316, rs1056890, and rs11160707 sites had a significantly superior overall survival compared to patients with a wild-type genotype (P=0.007). In the multivariable analysis, TRAF3 rs11160707 was found to be an independent favorable factor for progression-free survival (hazard ratio 0.428, P=0.028). CONCLUSIONS:
|
Authors | Juan Du, Jun Huo, Jun Shi, Zhengang Yuan, Chunyang Zhang, Weijun Fu, Hua Jiang, Qing Yi, Jian Hou |
Journal | Haematologica
(Haematologica)
Vol. 96
Issue 5
Pg. 729-37
(May 2011)
ISSN: 1592-8721 [Electronic] Italy |
PMID | 21228035
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Boronic Acids
- I-kappa B Proteins
- NF-kappa B p52 Subunit
- NFKB2 protein, human
- Pyrazines
- TNF Receptor-Associated Factor 3
- Bortezomib
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Base Sequence
- Boronic Acids
(administration & dosage)
- Bortezomib
- Female
- Gene Frequency
- Genetic Predisposition to Disease
(genetics)
- Genotype
- Haplotypes
- Humans
- I-kappa B Proteins
(genetics)
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Multiple Myeloma
(drug therapy, genetics)
- Multivariate Analysis
- NF-kappa B p52 Subunit
(genetics)
- Polymorphism, Single Nucleotide
- Pyrazines
(administration & dosage)
- Risk Assessment
- Risk Factors
- TNF Receptor-Associated Factor 3
(genetics)
- Treatment Outcome
|